Skip to main content

Table 3 Summary of primary and comorbid conditions reported by 53,963 patients seeking medical cannabis certification across five states

From: Comparing medical cannabis use in 5 US states: a retrospective database study

Condition Massachusetts
n = 27,892
n (%)
Colorado
n = 16,434
n (%)
Maine
n = 4591
n (%)
Connecticut
n = 2643
n (%)
Maryland
n = 2403
n (%)
Total
n = 61,379
%
Primary condition
 Chronic pain 5407 (19.4%) 12926 (78.7%) 1646 (35.9%) 42 (1.6%) 569 (23.7%) 38.8%
 Anxiety 6062 (21.7%) 5 (<0.1%) 581 (12.7%) 9 (0.3%) 487 (20.3%) 13.5%
 Post-traumatic stress disorder 1439 (5.2%) 456 (2.8%) 323 (7.0%) 1860 (70.4%) 126 (5.2%) 8.4%
 Back and neck problems 2737 (9.8%) 22 (0.1%) 590 (12.9%) 24 (0.9%) 273 (11.4%) 6.5%
 Arthritis 1785 (6.4%) 14 (0.1%) 232 (5.1%) 44 (1.7%) 142 (5.9%) 3.9%
 Insomnia 1811 (6.5%) 1 (0.0%) 169 (3.7%) 0 (0.0%) 76 (3.2%) 3.4%
 Cancer-related pain 752 (2.7%) 447 (2.7%) 84 (1.8%) 98 (3.7%) 48 (2.0%) 2.7%
 Depression 1050 (3.8%) 0 (0.0%) 58 (1.3%) 0 (0.0%) 102 (4.2%) 2.0%
 Migraines 810 (2.9%) 26 (0.2%) 136 (3.0%) 36 (1.4%) 54 (2.2%) 2.0%
 Muscle spasms 148 (0.5%) 780 (4.7%) 32 (0.7%) 0 (0.0%) 26 (1.1%) 1.7%
 ADD/ADHD 866 (3.1%) 0 (0.0%) 71 (1.5%) 0 (0.0%) 39 (1.6%) 1.6%
 Chronic nausea 248 (0.9%) 546 (3.3%) 60 (1.3%) 0 (0.0%) 16 (0.7%) 1.5%
 Fibromyalgia 448 (1.6%) 14 (0.1%) 57 (1.2%) 53 (2.0%) 28 (1.2%) 1.2%
 Headaches 292 (1.0%) 242 (1.5%) 94 (2.0%) 29 (1.1%) 15 (0.6%) 1.2%
 Spinal cord injury/disease 263 (0.9%) 0 (0.0%) 15 (0.3%) 192 (7.3%) 22 (0.9%) 0.9%
 Other 3774 (13.5%) 955 (5.8%) 443 (9.6%) 256 (9.7%) 380 (15.8%) 10.7%
Comorbid Conditions
 Anxiety 9815 (35.2%) 1226 (7.5%) 1543 (33.6%) 1534 (58.0%) 710 (29.5%) 28.3%
 Back and neck problems 7858 (28.2%) 1642 (10.0%) 1323 (28.8%) 807 (30.5%) 564 (23.5%) 23.7%
 Depression 8290 (29.7%) 481 (2.9%) 1059 (23.1%) 1014 (38.4%) 560 (23.3%) 21.9%
 Insomnia 9442 (33.9%) 740 (4.5%) 1157 (25.2%) 782 (29.6%) 491 (20.4%) 23.2%
 Chronic pain 6227 (22.3%) 1072 (6.5%) 1314 (28.6%) 653 (24.7%) 584 (24.3%) 18.2%
 Stress 7171 (25.7%) 73 (0.4%) 913 (19.9%) 947 (35.8%) 571 (23.8%) 11.2%
 Headaches 4569 (16.4%) 1339 (8.1%) 756 (16.5%) 487 (18.4%) 277 (11.5%) 14.2%
 Arthritis 5013 (18.0%) 700 (4.3%) 767 (16.7%) 452 (17.1%) 286 (11.9%) 14.0%
 Muscle spasms 3234 (11.6%) 2141 (13.0%) 668 (14.6%) 331 (12.5%) 277 (11.5%) 12.8%
 Migraines 3508 (12.6%) 692 (4.2%) 392 (8.5%) 362 (13.7%) 189 (7.9%) 9.9%
 Post-traumatic stress disorder 3265 (11.7%) 1257 (7.6%) 618 (13.5%) 114 (4.3%) 201 (8.4%) 10.0%
 ADD/ADHD 2855 (10.2%) 88 (0.5%) 366 (8.0%) 377 (14.3%) 216 (9.0%) 7.5%
 Mood disorders 2222 (8.0%) 30 (0.2%) 261 (5.7%) 308 (11.7%) 140 (5.8%) 6.0%
 Chronic nausea 1544 (5.5%) 1665 (10.1%) 350 (7.6%) 0 (0.0%) 77 (3.2%) 7.2%
 Neuropathic pain 1660 (6.0%) 165 (1.0%) 253 (5.5%) 200 (7.6%) 96 (4.0%) 4.8%
 Irritable bowel syndrome 1698 (6.1%) 82 (0.5%) 292 (6.4%) 197 (7.5%) 83 (3.5%) 4.6%
 Appetite stimulation 1875 (6.7%) 112 (0.7%) 256 (5.6%) 157 (5.9%) 102 (4.2%) 4.7%
 Fibromyalgia 967 (3.5%) 189 (1.2%) 173 (3.8%) 83 (3.1%) 48 (2.0%) 2.9%
 Spinal cord injury 928 (3.3%) 27 (0.2%) 131 (2.9%) 105 (4.0%) 63 (2.6%) 2.7%
 Obsessive compulsive behavior 904 (3.2%) 11 (0.1%) 89 (1.9%) 132 (5.0%) 45 (1.9%) 2.3%
  1. Table 3 provides a summary of the reported primary and comorbid conditions of patients seeking medical cannabis access at CB2 Insights clinics between November 2018 and March 2020 across five states. The total column includes all 61,379 patients included in the initial study for comparison, including patients from 12 states (Mahabir et al. 2020). Patients could only report one primary condition. All conditions that represented at least 2.0% of the sample in one state are listed, the remaining are grouped under “other”. Patients could report multiple comorbid conditions, but not the same comorbid condition as their primary. The top 20 are reported in the table. ADD = attention deficit disorder; ADHD = attention deficit hyperactivity disorder